南财智讯10月23日电，汉森制药公告，控股股东海南汉森持有的2450万股股份已解除质押，占其所持股 份比例11.56%，占公司总股本比例4.87%。截至公告日，海南汉森累计质押股份1000万股，占其所持股 份比例4.72%，占公司总股本比例1.99%。 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-020 湖南汉森制药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司""本公司"）于近日接到控股股 东海南汉森控股（有限合伙）（以下简称"海南汉森"）通知，获悉海南汉森所持有 本公司的部分股份已办理了解除质押手续，具体事项如下： | 股东 名称 | 是否 为控 股股 东 | 本次解除质 押股份数量 （股） | 占其所 持股份 比例(%) | 占公司 总股本 比例(%) | | 起始日 | | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 海南 汉森 | 是 | 24,500,000 | 11.56 | 4.87 | 2021 21 | 年 6 日 | 月 | 2025年10月 日 22 | 交通银行 股份有限 公司益阳 分行 | | 合计 | - | 24,500,000 | 11.56 | 4.87 ...

Group 1 - The core viewpoint of the news is that Hansoh Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant financing balances and a slight decline in net profit [1][2]. Group 2 - On October 16, Hansoh Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 33.34 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 4.74 million yuan, resulting in a net financing buy-in of -1.83 million yuan [1]. - As of October 16, the total financing and securities lending balance for Hansoh Pharmaceutical was 151 million yuan, with the financing balance accounting for 4.61% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, there were no shares repaid or sold on October 16, with the securities lending balance also at 0.00 shares, reflecting a high level compared to the past year [1]. Group 3 - Hansoh Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The main revenue sources for Hansoh Pharmaceutical include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and others, with a diverse product portfolio [2]. - As of August 29, the number of shareholders for Hansoh Pharmaceutical was 23,600, a decrease of 3.43% from the previous period, while the average circulating shares per person increased by 3.55% to 21,113 shares [2]. Group 4 - For the first half of 2025, Hansoh Pharmaceutical achieved an operating income of 509 million yuan, representing a year-on-year growth of 5.91%, while the net profit attributable to the parent company was 68.54 million yuan, a decrease of 31.80% year-on-year [2]. Group 5 - Since its A-share listing, Hansoh Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3].

Core Viewpoint - Hansen Pharmaceutical (002412) stated on September 26 that the company's operational data and other information will be disclosed in accordance with information disclosure rules in periodic reports, and specific details can be found in the company's announcements [1] Group 1 - The company engages with investors through an interactive platform to address inquiries [1] - The company emphasizes adherence to information disclosure regulations [1] - The company encourages stakeholders to refer to official announcements for detailed information [1]

Core Viewpoint - Hansen Pharmaceutical (002412) is currently in the process of scaling up the production technology for its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot study phase [1] Group 1 - The company is actively engaged in product research and development [1] - Cangrong Granules is a new drug derived from traditional Chinese medicine [1] - The product is currently undergoing process pilot testing [1]

Group 1 - The company has been asked about the proportion of innovative drugs in its R&D plans for the year [2] - The company stated that its traditional Chinese medicine new drug, Cangrong Granules, is currently in the process of pilot-scale research [2] - Further details regarding the company's R&D plans will be available in the 2024 annual report [2]

Group 1 - The core viewpoint of the article is that Hansen Pharmaceutical (002412) acknowledges that the fluctuations in its stock price in the secondary market are influenced by multiple factors, including macro policies, market trends, and investor preferences [1] - The company's management is committed to promoting the company's development and creating value for investors [1]

Core Viewpoint - The performance briefing held by Hunan Hansen Pharmaceutical Co., Ltd. focused on two main issues: the financial loss from investing in Sanxiang Bank and potential acquisition plans for Kangpu Pharmaceutical [1] Group 1: Financial Performance and Strategic Investments - The company acknowledged financial losses due to its investment in Sanxiang Bank, which is part of its "one body, two wings" development strategy aimed at maintaining its core traditional Chinese medicine business while expanding into the health industry and integrating financial services [1] - The company committed to timely information disclosure regarding any significant matters related to the transfer of its stake in Sanxiang Bank [1] Group 2: Potential Mergers and Acquisitions - Investors inquired about the possibility of acquiring Kangpu Pharmaceutical, in which the controlling shareholder Liu Ling'an increased his stake in 2021 [1] - The company stated that it would also disclose any future merger and acquisition activities in a timely manner [1] Group 3: Investor Communication - The performance briefing allowed direct communication between investors and the company's management, highlighting the company's commitment to transparency and timely information disclosure regarding strategic investments and potential acquisitions [1]

Group 1: Company Strategy - The company's main business is traditional Chinese medicine, and it has invested in Sanxiang Bank, which has led to financial losses. The company emphasizes that the investment is part of its "one body, two wings" development strategy, integrating traditional medicine with the health and financial industries [2]. - The company will disclose any significant matters related to the transfer of Sanxiang Bank's equity in a timely manner [2]. Group 2: Future Plans - There is a question regarding whether the company has plans to acquire Kangpu Pharmaceutical after the major shareholder Liu Ling'an increased his stake in 2021. The company stated that any future acquisition matters will also be disclosed promptly [2].

Group 1 - The company Hansen Pharmaceutical (002412) reported that as of August 29, 2025, the total number of shareholders, including those with credit accounts, is 23,580 [1]